Leuprorelin Sandoz

Leuprorelin, the active ingredient in Leuprorelin Sandoz, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a sterile injectable solution for subcutaneous use. It suppresses sex hormone production and is employed in the management of hormone‑dependent cancers and benign gynecological conditions in adults.

GNH USA supplies Leuprorelin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuprorelin is a GnRH agonist used in several hormone‑dependent conditions. - Prostate cancer: lowers testosterone levels to help control tumor growth. - Endometriosis: reduces estrogen stimulation of ectopic endometrial tissue, alleviating pain. - Uterine fibroids: diminishes fibroid size by suppressing ovarian hormone production. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis. - Breast cancer (adjuvant therapy): decreases circulating estrogen to support other systemic treatments.

Leuprorelin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Injection site reactions: pain, redness, or swelling at the subcutaneous site. - Headache: mild to moderate intensity. - Fatigue: general tiredness without exertion. - Nausea: occasional upset stomach. - Decreased libido: reduced sexual desire.

Serious or Rare Side Effects: - Bone mineral density loss: increased risk of fractures with long‑term therapy. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe allergic reaction: anaphylaxis, angioedema, or rash. - Pituitary apoplexy: sudden hemorrhage or infarction of the pituitary gland (extremely rare).

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Monitor hormone levels: check testosterone or estradiol periodically to confirm suppression. - Assess bone health: consider calcium, vitamin D supplementation and bone density testing for long‑term use. - Screen cardiovascular risk: evaluate blood pressure, lipid profile, and smoking status. - Use caution in hepatic impairment: adjust monitoring as liver function may affect drug handling. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines that influence hormonal pathways or cardiovascular risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Estrogen‑containing contraceptives: can reduce the intended hormonal suppression. - Anticoagulants (e.g., warfarin): hormonal changes may alter coagulation status.

Moderate Interactions (Monitor Closely): - Bisphosphonates: concurrent use may affect bone turnover monitoring. - Glucocorticoids: may exacerbate bone loss when combined with hormone suppression. - Thyroid hormone replacement: hormonal shifts can influence thyroid function tests.